Nov 09, 2016 4:05pm EST Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
Nov 08, 2016 8:00am EST Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
Nov 07, 2016 1:45pm EST Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016
Oct 27, 2016 10:05am EDT Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
Oct 18, 2016 8:00am EDT Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
Oct 12, 2016 9:15am EDT Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
Oct 09, 2016 10:00am EDT Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
